GlaxoSmithKline (GSK) Reports Q4 Adj-EPS of 34.4P, vs. Consensus of 33.5P
More News related to GSK
- Ligand Pharma (LGND) Announces that Glaxo (GSK) was Approved for Revolade Marketing in Europe
- Ligand Announces Approval for Revolade(R) in Europe
- Piper Jaffray Assumes Coverage on Human Genome Sciences (HGSI) with an Overweight; Benlysta's First Mover Advantage Key to $4bn+ Opportunity
- GlaxoSmithKline (GSK) ANnoujnces Sale of Entire Holding in Maxygen (MAXY)
- Organization Representing Minority and Women Owned Law Firms Praises $30 Million Corporate Commitment
More News related to Earnings
- Highlights From PALM's Q3 Conference Call: Recent Underperformance is Extremely Disappointing; Guides Well Below for Q4 Revenues
- Perry Ellis (PERY) Sees Strong Rebound In Q4 Profits
- Perry Ellis International Inc. (PERY) Posts Q4 EPS of $0.64, Tops by 5c; Guides FY11 EPS
GlaxoSmithKline (NYSE: GSK) reports Q4 EPS of 34.4 pence, which compares to the Street estimate of 33.5 pence.
Related Categories
EarningsStocks Mentioned
-0.65Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
